Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's weight-loss drug, as it widens its offerings ...

Hims & Hers Health Inc.’s shares jumped Tuesday after it said it was broadening its weight-loss offerings, adding access to ...

The telehealth-consultation platform said it plans to continue expanding its weight loss offerings.

Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges.

Eli Lilly quickly disassociated itself from Hims & Hers after the telehealth company said it was selling the pharmaceutical ...

Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment ...

Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as ...

The telehealth company Hims & Hers Health is expanding its weight-loss offerings by adding new medications to its platform.

Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly's weight loss ...

Hims & Hers (HIMS) stock slid Wednesday, a day after the company announced new weight-loss drug offerings — an update that ...

Hims & Hers Health (HIMS) is trying its best to stay relevant in the multi-billion dollar obesity treatment market. Despite a ...

April 1 (Reuters) - (This April 1 story has been corrected to say that the company also offers the branded version of Wegovy, not just cheaper versions of the treatment, in paragraph 3, and to ...